FSD Pharma Inc. (HUGE): Price and Financial Metrics


FSD Pharma Inc. (HUGE): $0.82

-0.02 (-2.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HUGE Stock Price Chart Interactive Chart >

Price chart for HUGE

HUGE Price/Volume Stats

Current price $0.82 52-week high $1.64
Prev. close $0.84 52-week low $0.69
Day low $0.79 Volume 20,852
Day high $0.84 Avg. volume 106,786
50-day MA $0.92 Dividend yield N/A
200-day MA $0.93 Market Cap 31.62M

FSD Pharma Inc. (HUGE) Company Bio


FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.


HUGE Latest News Stream


Event/Time News Detail
Loading, please wait...

HUGE Latest Social Stream


Loading social stream, please wait...

View Full HUGE Social Stream

Latest HUGE News From Around the Web

Below are the latest news stories about FSD PHARMA INC that investors may wish to consider to help them evaluate HUGE as an investment opportunity.

FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available

TORONTO, September 12, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it is presenting and participating via the on-demand session at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. FSD Pharma’s on-demand presentation can be acc

Yahoo | September 12, 2022

FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome

TORONTO, September 06, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it received "Study May Proceed" letter for the Investigational New Drug ("IND") application from the U.S. Food and Drug Administration ("FDA") and "Notice of Authorization" from Health Canada for its Phase 2

Yahoo | September 6, 2022

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium

TORONTO, July 13, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that is wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The new patent application is based on the results of completed preclinical animal toxicology studies and pha

Yahoo | July 13, 2022

FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates

TORONTO, June 27, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the results of its annual general meeting of shareholders ("AGM"), held online and in virtual-only format on June 23, 2022.

Yahoo | June 27, 2022

InvestmentPitch Media Video Discusses FSD Pharma’s Submission of an Investigational New Drug or “IND” Application with the U.S. Food and Drug Administration and Health Canada for Treatment of a Yet-To-Be-Disclosed Inflammatory Disorder

VANCOUVER, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has submitted an Investigational New Drug or “IND” application with the U.S. Food and Drug Administration and Health Canada. The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder. A Media Snippet accomp

Yahoo | June 1, 2022

Read More 'HUGE' Stories Here

HUGE Price Returns

1-mo -10.87%
3-mo 5.13%
6-mo -13.68%
1-year -46.75%
3-year -94.09%
5-year N/A
YTD -19.61%
2021 -34.62%
2020 -71.26%
2019 -87.37%
2018 755.60%
2017 -49.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5547 seconds.